KEYTRUDA® (pembrolizumab): Anti-PD-1 Therapy for patients with refractory cHL or who have relapsed after 3 or more prior lines of therapy. KEYTRUDA® (pembrolizumab): Anti-PD-1 Therapy for patients with refractory cHL or who have relapsed after 3 or more prior lines of therapy.

Anti–PD-1 Therapy Approved to Treat Both:

  • Patients with refractory classical Hodgkin lymphoma (cHL)
  • Patients with cHL who have relapsed after 3 or more prior lines of therapy

PD-1 = programmed death receptor-1.

Turn to KEYTRUDA for difficult-to-treat classical hodgkin lymphoma